pharmacogenomic interaction report
A document detailing how genetic variants affect drug metabolism, efficacy, and toxicity in cancer treatment.
Full Definition
A pharmacogenomic interaction report analyzes germline genetic variants in drug-metabolizing enzymes, transporters, and targets to predict individual drug responses. In oncology, these reports commonly include CYP2D6 status for tamoxifen metabolism, DPYD variants affecting fluoropyrimidine toxicity, and UGT1A1 polymorphisms influencing irinotecan dosing. The report guides dose modifications, drug selection, and toxicity monitoring strategies to optimize therapeutic outcomes while minimizing adverse effects.
Usage
Usage note: May be abbreviated as PGx report. Focus on germline variants affecting drug response rather than somatic tumor mutations.
In Context
- "The pharmacogenomic interaction report recommended a 25% irinotecan dose reduction due to UGT1A1*28 homozygosity." — Personalized dosing consultation
- "PGx reports enable proactive dose optimization before treatment initiation." — Clinical pharmacy protocol